Ji Yun Noh1,2, Joon Young Song1,2, Won Suk Choi1,2, Jacob Lee3, Yu Bin Seo3, Young Joo Kwon4, Gang Jee Ko4, Dae Ryong Cha4, Young Sun Kang4, Young-Ki Lee5, Hee Jin Cheong1,2, Woo Joo Kim1,2. 1. a Division of Infectious Diseases, Department of Internal Medicine , Korea University College of Medicine , Seoul , Korea. 2. b Asia Pacific Influenza Institute, Korea University College of Medicine , Seoul , Korea. 3. c Division of Infectious Diseases, Department of Internal Medicine , Hallym University College of Medicine , Chuncheon , Korea. 4. d Division of Nephrology, Department of Internal Medicine , Korea University College of Medicine , Seoul , Korea. 5. e Division of Nephrology, Department of Internal Medicine , Hallym University College of Medicine , Chuncheon , Korea.
Abstract
BACKGROUNDS: Patients with chronic kidney disease (CKD) are at an increased risk of morbidity and mortality from influenza. However, the immunogenicity of influenza vaccine is known to be attenuated in these patients. In this study, the immunogenicity of MF59-adjuvanted and non-adjuvanted trivalent influenza vaccines was compared in CKD patients undergoing hemodialysis (HD). METHODS:During 2013-2014, 179 CKD patients undergoing HD participated in the study. The patients were randomized into either MF59-adjuvanted vaccine group or non-adjuvanted vaccine group and were immunized with the respective vaccine. Sera were collected prior to vaccination and at 1 month (88 patients in MF59-adjuvanted vaccine group and 86 patients in non-adjuvanted vaccine group) and 6 months post vaccination. Levels of hemagglutination inhibition antibodies were measured. RESULTS: The seroconversion rate of all 3 vaccine strains at 1 month post-vaccination was significantly higher in the MF59-adjuvanted group than in the non-adjuvanted group (47.7% vs. 17.4%, A/H1N1; 42.0% vs. 16.3%, A/H3N2; 31.8% vs. 7.0%, B, P < 0.01). One month post-vaccination, the fold increase in geometric mean titer from pre-vaccination for A/H1N1, A/H3N2 and B viruses was significantly greater in the MF59-adjuvanted group than in the non-adjuvanted group. In elderly patients (≥65 years), the seroconversion rate at 1 month post-vaccination against influenza B strain was higher in the MF59-adjuvanted group than in the non-adjuvanted group (33.3% vs. 7.1%, P = 0.03). CONCLUSION: The MF59-adjuvanted influenza vaccine showed better immunogenicity than the non-adjuvanted influenza vaccine in CKD patients undergoing HD.
RCT Entities:
BACKGROUNDS: Patients with chronic kidney disease (CKD) are at an increased risk of morbidity and mortality from influenza. However, the immunogenicity of influenza vaccine is known to be attenuated in these patients. In this study, the immunogenicity of MF59-adjuvanted and non-adjuvanted trivalent influenza vaccines was compared in CKDpatients undergoing hemodialysis (HD). METHODS: During 2013-2014, 179 CKDpatients undergoing HD participated in the study. The patients were randomized into either MF59-adjuvanted vaccine group or non-adjuvanted vaccine group and were immunized with the respective vaccine. Sera were collected prior to vaccination and at 1 month (88 patients in MF59-adjuvanted vaccine group and 86 patients in non-adjuvanted vaccine group) and 6 months post vaccination. Levels of hemagglutination inhibition antibodies were measured. RESULTS: The seroconversion rate of all 3 vaccine strains at 1 month post-vaccination was significantly higher in the MF59-adjuvanted group than in the non-adjuvanted group (47.7% vs. 17.4%, A/H1N1; 42.0% vs. 16.3%, A/H3N2; 31.8% vs. 7.0%, B, P < 0.01). One month post-vaccination, the fold increase in geometric mean titer from pre-vaccination for A/H1N1, A/H3N2 and B viruses was significantly greater in the MF59-adjuvanted group than in the non-adjuvanted group. In elderly patients (≥65 years), the seroconversion rate at 1 month post-vaccination against influenza B strain was higher in the MF59-adjuvanted group than in the non-adjuvanted group (33.3% vs. 7.1%, P = 0.03). CONCLUSION: The MF59-adjuvanted influenza vaccine showed better immunogenicity than the non-adjuvanted influenza vaccine in CKDpatients undergoing HD.
Authors: Jungmin Son; Soo Bong Lee; Dong Won Lee; Il Young Kim; Su Jin Lee; Sun Min Lee; Sang Heon Song; Eun Young Seong; Ihm Soo Kwak Journal: Clin Exp Nephrol Date: 2012-09-19 Impact factor: 2.801
Authors: Sae Yoon Kee; Jin Soo Lee; Hee Jin Cheong; Byung Chul Chun; Joon Young Song; Won Suk Choi; Yu Mi Jo; Yoo Bin Seo; Woo Joo Kim Journal: J Infect Date: 2007-06-28 Impact factor: 6.072
Authors: David T Gilbertson; Kenneth J Rothman; Glenn M Chertow; Brian D Bradbury; M Alan Brookhart; Jiannong Liu; Wolfgang C Winkelmayer; Til Stürmer; Keri L Monda; Charles A Herzog; Akhtar Ashfaq; Allan J Collins; James B Wetmore Journal: J Am Soc Nephrol Date: 2019-01-24 Impact factor: 10.121
Authors: Dana C Miskulin; Daniel E Weiner; Hocine Tighiouart; Eduardo K Lacson; Klemens B Meyer; Taimur Dad; Harold J Manley Journal: Clin J Am Soc Nephrol Date: 2018-10-23 Impact factor: 8.237